Indication

In combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2279
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
09 November 2020
SMC meeting date:
06 October 2020
Patient group submission deadline:
03 August 2020